scholarly journals Expression of OPN3 in acral lentiginous melanoma and its associated with clinicohistopathologic features and prognosis

2021 ◽  
Author(s):  
Wen Zeng ◽  
Wei Zhang ◽  
Jianglong Feng ◽  
Xiaoyan He ◽  
Hongguang Lu
Keyword(s):  
Acral Lentiginous Melanoma

Acral lentiginous melanoma mimicking benign disease: The Emory experience

2003 ◽  
Vol 48 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Seaver L. Soon ◽  
Alvin R. Solomon ◽  
Diamondis Papadopoulos ◽  
Douglas R. Murray ◽  
Barbara McAlpine ◽  
...  
Keyword(s):  
Benign Disease ◽  
Acral Lentiginous Melanoma

Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma

2007 ◽  
Vol 0 (0) ◽  
pp. 071115063928004-???
Author(s):  
F.C. Muchemwa ◽  
D. Ma ◽  
Y. Inoue ◽  
J.A. Curtin ◽  
B.C. Bastian ◽  
...  
Keyword(s):  
Phosphatidyl Inositol ◽  
Signalling Pathway ◽  
Acral Lentiginous Melanoma ◽  
Constitutive Activation

Incidence, timing, and predictors of CNS metastasis in patients (Pts) with clinically localized cutaneous melanoma (CM).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9580-9580
Author(s):  
Merve Hasanov ◽  
Denai R. Milton ◽  
Sapna Pradyuman Patel ◽  
Hussein Abdul-Hassan Tawbi ◽  
Isabella Claudia Glitza ◽  
...  
Keyword(s):  
Primary Tumor ◽  
Cumulative Incidence ◽  
Tumor Location ◽  
Initial Diagnosis ◽  
Stage I ◽  
Acral Lentiginous Melanoma ◽  
Primary Tumor Location ◽  
Cns Metastasis ◽  
Increased Risk

9580 Background: Surveillance for CNS metastasis (mets) is not routinely performed in pts with clinically localized CM. Improved understanding of the incidence, timing and risk factors for the development of CNS metastasis in these pts may inform surveillance strategies. Methods: Under an IRB-approved protocol, demographics, tumor characteristics, and clinical events were collected for pts diagnosed from 1998 to 2019 with AJCC 8th edition stage I or II CM at MD Anderson Cancer Center. Dates of initial diagnosis, regional, distant non-CNS, and CNS mets were recorded. Symptoms and the extent of disease (brain, LMD, both) were recorded for pts with CNS mets. Cumulative incidence of distant mets (CNS and non-CNS) was determined using the competing risks method, including death; pts without CNS mets and alive at last follow-up were censored. Differences in cumulative incidence between groups were assessed using Gray’s test. Associations between measures of interest and cumulative incidence were determined using proportional subdistribution hazards regression models. All statistical tests used a significance level of 5%. Results: 5,179 Stage I-II CM pts were identified. At a median follow up of 82 (0.0-268.8) months, 703 (13.6%) pts were diagnosed with distant mets, including 355 (6.9%) with CNS mets. Cumulative incidence of CNS mets was 0%, 2%, and 5% at 1, 2, and 5 years, respectively. Among pts with distant mets, the first site of distant mets was CNS only for 29 (4%), non-CNS only for 557 (79%), and both for 116 (17%) pts. At initial diagnosis of CNS mets, 195 (55%) pts were asymptomatic, and 46 (13%) had no active extracranial disease. Median time to any distant met was longer for pts who were diagnosed with CNS mets [40.0 (1.9-238.0) months] vs pts diagnosed with non-CNS mets only [31.4 (1.1-185.7) months, p < 0.001]. On multivariable analysis, risk of CNS mets was significantly associated with primary tumor location of scalp [Hazard Ratio (HR) 3.4, 95% Confidence interval (CI) 1.9-5.9], head/neck (HR 3.3, 95% CI 2.0-5.3), or trunk (HR 2.3, 95% CI 1.5-3.5) (vs upper extremity); acral lentiginous melanoma subtype (HR 2.0, 95% CI 1.2-3.6) (vs superficial spreading); increased T category (T2 HR 1.5, 95% CI 1.1-2.2; T3 HR 1.9, 95% CI 1.2-3.0; T4 HR 2.1, 95% CI 1.1-3.8; vs T1), Clark level (CL) (CL4 HR 2.1, 95% CI 1.2-3.7 vs CL2), and mitotic rate (MR) (MR 5-9/mm2 HR 2.1, 95% CI 1.5-3.0; MR > 9/mm2 HR 2.0, 95% CI 1.3-3.0; vs MR 0-4/mm2). While high ( > 9/mm2) MR was associated with increased risk of CNS and non-CNS mets, intermediate (5-9/mm2) was associated with CNS mets only. Conclusions: Primary tumor location, tumor thickness, and MR were strongly associated with risk of CNS mets. MR rate was more strongly associated with risk of CNS than non-CNS mets. Validation in independent cohorts may provide evidence to support CNS surveillance strategies in select pts with stage I-II CM who are deemed high risk for CNS mets.

scholarly journals Melanoma: clinical-pathological and molecular analysis in patients of Ibague city, Colombia

Duazary ◽  
2020 ◽  
Vol 17 (1) ◽  
pp. 5-18 ◽  
Author(s):  
Carlos Puentes ◽  
Ana Estrada ◽  
Mabel Bohórquez ◽  
Anggi Vélez ◽  
Carlos Giraldo ◽  
...  
Keyword(s):  
Gene Mutations ◽  
Mitotic Rate ◽  
Clinicopathological Characteristics ◽  
Lower Limbs ◽  
Braf Gene ◽  
Acral Lentiginous Melanoma ◽  
Kaplan Meier ◽  
Age Of Diagnosis ◽  
Pathology Reports ◽  
Clinicopathological Variables

This study aimed to establish the clinicopathological characteristics of patients with melanoma and its association with BRAF gene mutations. The pathology reports and paraffin-embedded tumor samples from 47 women and 30 men with melanoma, with an average age of diagnosis of 60 years, were reviewed at the Hospital Federico Lleras Acosta of Ibague, between 2010 and 2016. The presence of V600E mutation at the exon 15 of BRAF gene, was analyzed in these tumoral samples by Sanger sequencing and visual inspection of the electropherograms. We also studied the clinicopathological variables with X2, t-Student and the Kaplan Meier index. Most of the lesions were located in the lower limbs (46.6%). The most frequent subtype was Acral Lentiginous Melanoma (41.8%). Most lesions were of poor prognosis: Breslow depth greater than 4.1 mm (52.7%), ulceration (61.4%) and medium or high mitotic rate (> 30 %). The V600E mutation was identified in five patients with large, deep and ulcerated tumors, four of them had less than four years of survival. In conclusion, there was a higher frequency of melanoma in women, V600E BRAF mutation was present in patients with advanced disease (high Breslow index) and, the probability of five-year survival was less than 40%.

scholarly journals A Case of Delayed Diagnosis of Acral Lentiginous Melanoma

2015 ◽  
Vol 28 (6) ◽  
pp. 439-443
Author(s):  
Michaela Qottvaldová ◽  
Hana Jedličková ◽  
Alexandr Poprach ◽  
Vladimír Vašků
Keyword(s):  
Delayed Diagnosis ◽  
Acral Lentiginous Melanoma

Acral Lentiginous Melanoma

1980 ◽  
Vol 116 (7) ◽  
pp. 773 ◽  
Author(s):  
William P. Coleman
Keyword(s):  
Acral Lentiginous Melanoma
Sign in / Sign up

Export Citation Format

Share Document